市场调查报告书
商品编码
1370614
章鱼壶心肌症治疗市场-按疗法(DAPT、抗凝血剂、β 受体阻断剂、他汀类药物、利尿剂、ACE 抑制剂)、给药途径(口服、肠胃外)、配销通路(医院、零售药局)、全球预测,(2022-2032 年)Takotsubo Syndrome Therapeutics Market-By Therapy (DAPT, Anticoagulants, Beta-blockers, Statins, Diuretics, ACE Inhibitors), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital, Retail Pharmacies), Global Forecast, (2022-2032) |
2023 年至 2032 年,全球 Takotsubo 症候群治疗市场将以 4.7% 的复合年增长率成长。对病情的更好了解和改进的诊断技术带来了更准确和及时的治疗,从而推动了市场成长。医疗保健专业人员和一般大众对这种综合症的认识不断提高,导致了早期干预,预计这将推动行业扩张。
此外,开发用于解决与压力相关的心臟病根本原因的药物和疗法将有助于业务成长。现代社会与压力相关的疾病发生率不断上升,增加了对有效的章鱼壶综合症疗法的需求,推动了市场的扩张。
2022 年 2 月,高德美和 Taro Pharmaceutical Industries Ltd. 宣布达成正式协议,其中 Taro 将从高德美收购 Alchemee(之前称为 The Proactiv Company (TPC))。
整个市场根据治疗、给药途径、配销通路和地区进行分类。
根据治疗情况,由于需要管理与病情相关的血栓併发症,抗凝血剂细分市场在分析期间的复合年增长率将达到 4.8%。抗凝血剂对于预防血栓和最大限度地降低中风或其他心血管併发症的风险至关重要,从而改善患者护理和治疗结果。
肠胃外给药途径预期 2023-2032 年复合年增长率为 4.3%。对快速和直接药物传输的需求将促进该领域的成长。肠外给药可确保立即和精确的药物分配,这对于管理急性章鱼壶发作和实现有效症状缓解至关重要。
根据配销通路,到 2032 年,零售药局领域的复合年增长率将达到 4.4%。零售药局提供的可及性和患者便利性将推动该领域的成长。零售药局可以轻鬆获得处方药,使患者更方便地获得必要的治疗药物并坚持治疗方案,从而改善患者的治疗效果。
从地区来看,亚太地区 takotsubo 症候群治疗市场在整个预测期内的复合年增长率将达到 5.4%。意识的提高、医疗基础设施的改善、心血管疾病盛行率的上升以及人口老化将推动该地区的产业发展。不断变化的医疗保健优先事项推动了治疗研究和开发,进一步刺激了成长。
Global Takotsubo syndrome therapeutics market will grow at 4.7% CAGR from 2023 to 2032. Better understanding of the condition and improved diagnostic techniques have led to more accurate and timely treatment, fueling market growth. Increased awareness of the syndrome among healthcare professionals and the general population has led to earlier intervention, which is expected to drive industry expansion.
Additionally, the development of medications and therapies for addressing the underlying causes of stress-related heart conditions will contribute to business growth. The rising incidence of stress-related disorders in modern society has heightened the demand for effective takotsubo syndrome therapeutics, propelling market expansion.
In February 2022, Galderma and Taro Pharmaceutical Industries Ltd. announced a formal agreement wherein Taro would acquire Alchemee, previously known as The Proactiv Company (TPC), from Galderma.
The overall market is categorized based on therapy, route of administration, distribution channel, and region.
Based on therapy, the anticoagulants segment will reflect a 4.8% CAGR during the analysis period, driven by the need to manage thrombotic complications associated with the condition. Anticoagulants are crucial in preventing blood clots and minimizing the risk of stroke or other cardiovascular complications, thereby enhancing patient care and outcomes.
The parenteral route of administration segment is expected to exhibit a 4.3% CAGR during 2023-2032. The need for rapid and direct drug delivery will foster growth in the segment. Parenteral administration ensures immediate and precise medication distribution, which is crucial in managing acute takotsubo episodes and achieving effective symptom relief.
Based on distribution channel, the retail pharmacies segment will depict a 4.4% CAGR through 2032. The accessibility and patient convenience offered by retail pharmacies will drive growth in the segment. Retail pharmacies offer easy access to prescribed medications, making it more convenient for patients to obtain necessary therapeutics and adhere to treatment regimens, improving patient outcomes.
Regionally, the Asia Pacific takotsubo syndrome therapeutics market will witness a 5.4% CAGR throughout the forecast period. Growing awareness, better healthcare infrastructure, rising cardiovascular disease prevalence, and an aging population will boost the region's industry. Evolving healthcare priorities drive therapeutic research and development, further spurring growth.